AccessibilityHelpAbout Us
Compugen logo

Compugen(NASDAQ) CGEN

Market Cap$221.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-79%
5 Year-62%
1 Year+64%
1 Month-10%
Premium Feature
Moneyball Superscore
73/100
$2.37
+1.28%
+0.03Today
After hours$2.38+$0.01 (+0.21%)
Compugen last closing stock price
MetricPriceDate
Last closeUSD 2.342026-09-23
Compugen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.9%USD 2.412026-09-16
1 month-9.65%USD 2.592026-08-24
3 month+15.84%USD 2.022026-06-25
Year to date+52.94%USD 1.532025-12-31
1 year+63.64%USD 1.432025-09-23
3 year+138.73%USD 0.982023-09-22
5 year-62.38%USD 6.222021-09-24
Since inception-78.97%USD 11.132000-08-11

Compugen Financials at a Glance

Market Cap

$221.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$74.00M

Net Income (TTM)

$35.19M

EPS (TTM)

$0.37

P/E Ratio

6.32

Dividend

$0.00

Beta (Volatility)

1.64 (High)

Price

$2.37

Volume

101,488.065

Open

$2.34

Previous Close

$2.34

Daily Range

$2.33 - $2.37

52-Week Range

$1.37 - $3.24

Estimated Earnings Date

Nov 9, 2026

CGEN News

vir biotechnology

Why Compugen Shares Are Up Today

James HalleyFeb 28, 2023
Two people seated at a lab desk featuring a PC screen and microscope

Why Compugen Stock Got Slammed Today

Eric VolkmanFeb 8, 2023
smiling healthcare nurse

Why Shares of Compugen Rose on Thursday

James HalleyDec 29, 2022
GettyImages-1294339670

Why Shares of Compugen Rose 16.5% on Wednesday

James HalleyNov 30, 2022
male scientist looking through microscope

Why Shares of Compugen Jumped 17.86% on Thursday

James HalleyNov 17, 2022

Why Compugen Stock Crumbled Today

Eric VolkmanNov 14, 2022
GettyImages-1193974970

Why Shares of Compugen Jumped 9.27% on Tuesday

James HalleyNov 1, 2022
Microscope next to test tubes

Why Compugen Stock Got Slammed Today

Eric VolkmanNov 15, 2021
Page 1

CGEN: Motley Fool Moneyball Superscore

73

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Compugen

Compugen Ltd. is a clinical-stage biotechnology company based in Israel, focused on the discovery and development of innovative therapeutic candidates. Established in 1993, the company operates in the fields of immuno-oncology, with a robust pipeline of investigational treatments aimed at addressing various solid tumors.

Products and Services
  • COM701: An anti-PVRIG antibody in Phase I clinical trials for solid tumors
  • COM902: A therapeutic antibody targeting TIGIT, also in Phase I trials
  • Bapotulimab: An antibody targeting ILDR2, currently in Phase I development
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials, enhancing market potential
  • Strategic partnerships with major pharmaceutical companies like Bayer and Bristol-Myers Squibb
  • Focus on myeloid targets, expanding research capabilities and therapeutic options
Financial Highlights
  • Recent quarterly revenue of $2.6 million, showing growth from previous quarters
  • Trailing twelve months (TTM) net profit margin of 47.55%, indicating operational efficiency
  • Current ratio of 5.72, reflecting strong liquidity and financial health
Compugen Ltd. is positioned in a dynamic sector with significant growth potential. The company's focus on immuno-oncology and strategic collaborations with industry leaders enhances its ability to innovate and bring new therapies to market. Recent financial performance indicates a solid foundation, with a strong liquidity position and a growing revenue stream. The ongoing clinical trials and partnerships suggest that Compugen is well-equipped to capitalize on emerging opportunities in the biotechnology landscape.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

75

CEO

Eran Ophir, PhD

Website

www.cgen.com

Headquarters

Holon, TA 5885849, IL

CGEN Financials

Key Financial Metrics (TTM)

Gross Margin

86.89%

Operating Margin

40.94%

Net Income Margin

47.55%

Return on Equity

42.57%

Return on Capital

29.64%

Return on Assets

25.43%

Earnings Yield

15.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$221.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

94.73M

Volume

101.49K

Avg. Volume

268.29K

Financials (TTM)

Gross Profit

$64.30M

Operating Income

$30.30M

EBITDA

$35.24M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$125.30M

Total Debt

$3.02M

Compugen Performance Analysis

Compugen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 7,500,00025.0%
20232023-12-31USD 33,459,000346.1%
20242024-12-31USD 27,864,000-16.7%
20252025-12-31USD 72,764,000161.1%
Compugen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3050.4%
Q42025-12-313460.7%
Q12026-03-31-96.8%
Q22026-06-3019.6%
Compugen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.39-4.2%
20232023-12-31USD -0.21-45.0%
20242024-12-31USD -0.16-25.7%
20252025-12-31USD 0.38N/A
Compugen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.0%
Q42025-12-31904.3%
Q12026-03-31-113.3%
Q22026-06-3012.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.60M

+107.0%

Gross Profit

-$92.00K

+77.5%

Gross Margin

-3.54%

N/A

Market Cap

$221.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.96M

N/A

Employees

75

N/A

Net Income

-$7.01M

+4.6%

EBITDA

-$7.00M

+4.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$125.30M

+33.5%

Total Debt

$3.02M

+1.8%

Accounts Receivable

$4.11M

+9.1%

Inventory

$0.00

N/A

Long Term Debt

$2.40M

-4.0%

Short Term Debt

$623.00K

+32.3%

Return on Assets

25.43%

N/A

Return on Invested Capital

26.18%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPHAInnate Pharma S.A.
$1.72-2.27%
MOLNMolecular Partners AG
$4.19-2.56%
TNXPTonix Pharmaceuticals Holding Corp.
$9.70-5.27%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$7.45-3.75%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.32+82.65%
ONDSOndas
$7.61+2.77%
INTCIntel
$127.24+3.78%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.62-0.12%

Questions About CGEN

What is the current price of Compugen?

Compugen is trading at $2.36 per share.

What is the 52-week range for Compugen?

Over the past 52 weeks, Compugen has traded between $1.37 and $3.24.

How much debt does Compugen have?

As of the most recent reporting period, Compugen reported total debt of $3.02M.

How much cash does Compugen have on hand?

Compugen reported $10.28M in cash and cash equivalents in its most recent financial results.

What is Compugen’s dividend yield?

Compugen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services